Ivosidenib, developed as AG-120 and marketed as Tibsovo, is a small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) used in biomarker-defined leukemia care. Unlike cytotoxic chemotherapy, it does not aim to kill dividing cells directly; it interferes with an abnormal metabolic signal that keeps malignant blasts immature. This article explains the mutant-IDH1 mechanism and why measuring the oncometabolite 2-hydroxyglutarate is central to how the drug is understood. The 250 mg oral tablet is the dose form used in this mutation-defined setting for outpatient care.
Normal IDH1 helps convert isocitrate to alpha-ketoglutarate in cellular metabolism. A gain-of-function mutation, most often at the R132 codon, reshapes the enzyme so it instead produces 2-hydroxyglutarate (2-HG), an oncometabolite that blocks the normal maturation of blood-forming cells. Ivosidenib binds the mutant enzyme and reduces 2-HG production, which relieves that block and allows immature blast cells to differentiate toward normal lineages, a distinctive way of acting compared with conventional AML agents. This metabolic route separates ivosidenib from cytotoxic agents that act on dividing cells regardless of genotype.
Therapy is reserved for cases with a confirmed IDH1 mutation, so companion testing precedes treatment. Trials in IDH1-mutant disease, including studies in previously treated cholangiocarcinoma and in newly diagnosed unresectable AML, shaped the clinical profile. Because the target is a single mutant enzyme, the question of acquired resistance and sequential therapy is a routine part of long-term planning, and re-testing at progression informs the next step. Symptom and blast-count changes are tracked alongside the biomarker, since the mechanism acts through maturation rather than rapid cell kill. Combination with other AML agents follows the resistance picture rather than a fixed calendar. Careful monitoring for differentiation syndrome remains part of managing this mechanism-based therapy in practice. Documenting the mutation and the response over time supports the long-term evidence base for this targeted approach.
Q: What exactly does Ivosidenib block? A: It inhibits mutant IDH1, the variant enzyme that produces the oncometabolite 2-hydroxyglutarate, rather than the normal wild-type enzyme.
Q: Why is 2-hydroxyglutarate important? A: Elevated 2-HG stalls cell differentiation; lowering it lets immature blast cells mature, which is the mechanism behind the therapy's effect.
Q: Is mutation testing required before use? A: Yes. The drug targets mutant IDH1, so an IDH1 mutation must be confirmed by an accepted assay before treatment begins.
Ivosidenib, developed as AG-120 and marketed as Tibsovo, is a small-molecule inhibitor of mutant isocitrate dehydrogenase-1 (IDH1) used in biomarker-defined leukemia care. Unlike cytotoxic chemotherapy, it does not aim to kill dividing cells directly; it interferes with an abnormal metabolic signal that keeps malignant blasts immature. This article explains the mutant-IDH1 mechanism and why measuring the oncometabolite 2-hydroxyglutarate is central to how the drug is understood. The 250 mg oral tablet is the dose form used in this mutation-defined setting for outpatient care.
Normal IDH1 helps convert isocitrate to alpha-ketoglutarate in cellular metabolism. A gain-of-function mutation, most often at the R132 codon, reshapes the enzyme so it instead produces 2-hydroxyglutarate (2-HG), an oncometabolite that blocks the normal maturation of blood-forming cells. Ivosidenib binds the mutant enzyme and reduces 2-HG production, which relieves that block and allows immature blast cells to differentiate toward normal lineages, a distinctive way of acting compared with conventional AML agents. This metabolic route separates ivosidenib from cytotoxic agents that act on dividing cells regardless of genotype.
Therapy is reserved for cases with a confirmed IDH1 mutation, so companion testing precedes treatment. Trials in IDH1-mutant disease, including studies in previously treated cholangiocarcinoma and in newly diagnosed unresectable AML, shaped the clinical profile. Because the target is a single mutant enzyme, the question of acquired resistance and sequential therapy is a routine part of long-term planning, and re-testing at progression informs the next step. Symptom and blast-count changes are tracked alongside the biomarker, since the mechanism acts through maturation rather than rapid cell kill. Combination with other AML agents follows the resistance picture rather than a fixed calendar. Careful monitoring for differentiation syndrome remains part of managing this mechanism-based therapy in practice. Documenting the mutation and the response over time supports the long-term evidence base for this targeted approach.
Q: What exactly does Ivosidenib block? A: It inhibits mutant IDH1, the variant enzyme that produces the oncometabolite 2-hydroxyglutarate, rather than the normal wild-type enzyme.
Q: Why is 2-hydroxyglutarate important? A: Elevated 2-HG stalls cell differentiation; lowering it lets immature blast cells mature, which is the mechanism behind the therapy's effect.
Q: Is mutation testing required before use? A: Yes. The drug targets mutant IDH1, so an IDH1 mutation must be confirmed by an accepted assay before treatment begins.
english
français
Deutsch
Italiano
Русский
Español
português
Nederlandse
ελληνικά
日本語
한국
العربية
हिन्दी
Türkçe
indonesia
tiếng Việt
ไทย
বাংলা
فارسی
polski
